Farmaka
Vol 19, No 1 (2021): Farmaka (Maret)

REVIEW ARTIKEL: TUMBUHAN HERBAL SEBAGAI TERAPI KOMPLEMEN KANKER PARU

BRIGITTA TIARA PUTRI PRIYANTONO (260110170151)
ANAS SUBARNAS (Unknown)



Article Info

Publish Date
31 Mar 2021

Abstract

AbstrakKematian akibat kanker paru menduduki peringkat pertama di dunia, termasuk di Indonesia, apabila dibandingkan dengan jenis kanker lainnya. Terapi utama penyakit ini adalah kemoterapi dan operasi. Tetapi, pasien yang hanya menjalani terapi konvensional tersebut seringkali mengalami efek samping yang tidak diinginkan seperti mual, diare, depresi, dan sulit tidur. Konsumsi herbal yang merupakan bagian dari terapi komplemen dan alternatif telah banyak digunakan dalam pengobatan berbagai jenis penyakit. Hasil dari studi literatur ini menunjukkan bahwa penggunaan herbal sebagai terapi komplemen dalam pengobatan kanker paru dapat meningkatkan kualitas hidup dan meringankan efek samping dari kemoterapi.Kata Kunci: kanker paru, terapi komplemen, herbalAbstractLung cancer deaths are ranked first in the world, including in Indonesia, compared with other types of cancer. The main treatment of this disease is chemotherapy and surgery. However, patients who only underwent conventional therapy often experience unwanted side effects such as nausea, diarrhea, depression and sleeplessness. Consumption of herb that is part of complementary and alternative medicine has been widely used in the treatment of various diseases. The results of this literature study show that the use of herbs as complement therapy in lung cancer management can improve quality of life and alleviate the side effects of chemotherapy.Keywords: lung cancer, complement therapy, herbs

Copyrights © 2021






Journal Info

Abbrev

farmaka

Publisher

Subject

Biochemistry, Genetics & Molecular Biology Chemistry Health Professions Immunology & microbiology Materials Science & Nanotechnology Medicine & Pharmacology Public Health

Description

Farmaka is replacement for Pharmaceutical Bulletin, published since 1991, with a frequency of four times a year. Editors accept scholarly works of research results and literature review which was closely related to the science, pharmaceutical technology and ...